We're going to get started. Thank you, everyone, for joining us here in Berlin, and there are many more of you that are online. Welcome to the solid tumor update that we're having at ESMO 2025. We're ...

The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...

A working model showing that CAFs exhibit profound amino acid reprogramming, especially the production of glycine, in CRC. CRC cell‐derived TGF‐β1 activates de novo glycine synthesis in CAFs, ...

A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal ...

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development ...

One of the best ways to defeat cancer is by rousing the immune system to attack it. Experts have thought that immune cells had to be inside of tumors for one type of immunotherapy, known as checkpoint ...